Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure

Circulation: Heart Failure

Volumn 7, Issue 3, 2014, Pages 448-456

  Masci, Pier Giorgio ^a   Doulaptsis, Constantinos ^b   Bertella, Erika ^c   Del Torto, Alberico ^a,e   Symons, Rolf ^b   Pontone, Gianluca ^c   Barison, Andrea ^a   Droogné, Walter ^b   Andreini, Daniele ^c,d   Lorenzoni, Valentina ^e   Gripari, Paola ^c   Mushtaq, Saima ^c   Emdin, Michele ^a   Bogaert, Jan ^b   Lombardi, Massimo ^a  

^a CNR   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Cardiomyopathies; Fibrosis; Magnetic resonance imaging

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONGESTIVE HEART FAILURE; DISEASE DURATION; FEMALE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE FIBROSIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SUDDEN CARDIAC DEATH; TERTIARY CARE CENTER;

CARDIOMYOPATHIES; FIBROSIS; MAGNETIC RESONANCE IMAGING;

ADULT; AGED; CARDIOMYOPATHIES; COHORT STUDIES; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84902765162     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000996     Document Type: Article

References (35)

1. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375:752-762.
2. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long- term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-1084.
3. Masci PG, Barison A, Aquaro GD, Pingitore A, Mariotti R, Balbarini A, Passino C, Lombardi M, Emdin M. Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. Int J Cardiol. 2012;157:43-47.
4. Redfield MM, Gersh BJ, Bailey KR, Rodeheffer RJ. Natural history of incidentally discovered, asymptomatic idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;74:737-739.
5. Aleksova A, Sabbadini G, Merlo M, Pinamonti B, Barbati G, Pyxaras S, Lo Giudice F, Perkan A, di Lenarda A, Sinagra G. Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure-a subgroup analysis from the Trieste Cardiomyopathy Registry. J Cardiovasc Med (Hagerstown). 2009;10:699-705.
6. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977-982.
7. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, Rodeheffer RJ. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/ American Heart Association heart failure staging criteria in the community. Circulation. 2007;115:1563-1570.
8. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, Wosornu D, Lancashire RJ. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001;358:439-444.
9. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829-833.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
11. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985.
12. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke DA, Gerstenblith G, Marbán E, Tomaselli GF, Lima JA. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414-2421.
13. Lehrke S, Lossnitzer D, Schöb M, Steen H, Merten C, Kemmling H, Pribe R, Ehlermann P, Zugck C, Korosoglou G, Giannitsis E, Katus HA. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97:727-732.
14. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896-908.
15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Spencer KT, St John Sutton M, Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108
16. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210-218.
17. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417-426.
18. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. AHA Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. Circulation. 2002;105:539-542.
19. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML; MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol. 2004;43:1459-1465.
20. Uno H, Tian L, Cai T, Kohane IS, Wei LJ. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med. 2013;32:2430-2442.
21. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol. 1987;60:1340-1355.
22. Unverferth DV, Baker PB, Swift SE, Chaffee R, Fetters JK, Uretsky BF, Thompson ME, Leier CV. Extent of myocardial fibrosis and cellular hypertrophy in dilated cardiomyopathy. Am J Cardiol. 1986;57:816-820.
23. Mann DL. Mechanisms and models in heart failure. Circulation. 1999;100:999-1088.
24. Masci PG, Schuurman R, Andrea B, Ripoli A, Coceani M, Chiappino S, Todiere G, Srebot V, Passino C, Aquaro GD, Emdin M, Lombardi M. Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging. 2013;6:790-799.
25. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980-984.
26. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation. 1994;90:2772-2779.
27. Grzybowski J, Bilińska ZT, Ruzyo W, Kupść W, Michalak E, Szcześniewska D, Poplawska W, Rydlewska-Sadowska W. Determinants of prognosis in nonischemic dilated cardiomyopathy. J Card Fail. 1996;2:77-85.
28. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564-1575.
29. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;57:1468-1476.
30. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:2388-2442.
31. Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, Taylor AJ. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011;57:821-828.
32. Bogun FM, Desjardins B, Good E, Gupta S, Crawford T, Oral H, Ebinger M, Pelosi F, Chugh A, Jongnarangsin K, Morady F. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53:1138-1145.
33. Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol. 1992;70:1180-1184.
34. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Pilotto A, Pasotti M, Jenkins S, Rowland C, Aslam U, Wilde AA, Perrot A, Pankuweit S, Zwinderman AH, Charron P, Pinto YM. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59:493-500.
35. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580.